Literature DB >> 9203673

An ELISA for detection of antibodies to the E2 protein of GB virus C.

B J Dille1, T K Surowy, R A Gutierrez, P F Coleman, M F Knigge, R J Carrick, R D Aach, F B Hollinger, C E Stevens, L H Barbosa, G J Nemo, J W Mosley, G J Dawson, I K Mushahwar.   

Abstract

An ELISA was developed for detection of antibodies to GB virus C (GBV-C) using a recombinant E2 protein expressed in CHO cells. Seroconversion to anti-E2 positivity was noted among several persons infected with GBV-C RNA-positive blood through transfusion. Of 6 blood recipients infected by GBV-C RNA-positive donors, 4 (67%) became anti-E2 positive and cleared their viremia. Thus, anti-E2 seroconversion is associated with viral clearance. The prevalence of antibodies to E2 was relatively low (3.0%-8.1%) in volunteer blood donors but was higher in several other groups, including plasmapheresis donors (34.0%), intravenous drug users (85.2%), and West African subjects (13.3%), all of whom tested negative by GBV-C reverse-transcription polymerase chain reaction (RT-PCR). These data demonstrate that testing for anti-E2 should greatly extend the ability of RT-PCR to define the epidemiology and clinical significance of GBV-C.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9203673     DOI: 10.1093/infdis/175.2.458

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  19 in total

1.  Prokaryotical expression of structural and non-structural proteins of hepatitis G virus.

Authors:  N S Xia; H J Yang; J Zhang; C Q Lin; Y B Wang; J Wang; M Y Zhan; M Ng
Journal:  World J Gastroenterol       Date:  2001-10       Impact factor: 5.742

2.  Relation between GB virus C/hepatitis G virus and fulminant hepatic failure may be secondary to treatment with contaminated blood and/or blood products.

Authors:  R Halasz; L Barkholt; C Lara; C Hultgren; Y Ando; U Broomé; B Fischler; A Nemeth; B G Ericzon; A Sönnerborg; M Sällberg
Journal:  Gut       Date:  1999-02       Impact factor: 23.059

3.  Identification of hepatitis G virus particles in human serum by E2-specific monoclonal antibodies generated by DNA immunization.

Authors:  S Schmolke; M Tacke; U Schmitt; A M Engel; B Ofenloch-Haehnle
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

4.  Hepatitis G virus coinfection in chronic hepatitis B and C patients in Poland.

Authors:  M Radkowski; W Stańczak; B Walewska-Zielecka; T Loch; J Cianciara; L F Wang; T Laskus
Journal:  Infection       Date:  1998 Mar-Apr       Impact factor: 3.553

5.  Immunoreactivity to putative B-cell epitopes of hepatitis G virus polyprotein in viremic and nonviremic subjects.

Authors:  P Toniutto; C Fabris; F Barbone; S G Tisminetzky; D Liani; T Galai; G Barillari; F Biffoni; V Gasparini; M Pirisi
Journal:  Clin Diagn Lab Immunol       Date:  1999-07

Review 6.  GB virus C/hepatitis G virus (GBV-C/HGV): still looking for a disease.

Authors:  M Sathar; P Soni; D York
Journal:  Int J Exp Pathol       Date:  2000-10       Impact factor: 1.925

7.  New DNA viruses identified in patients with acute viral infection syndrome.

Authors:  Morris S Jones; Amit Kapoor; Vladimir V Lukashov; Peter Simmonds; Frederick Hecht; Eric Delwart
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

8.  In vitro infection of human peripheral blood mononuclear cells by GB virus C/Hepatitis G virus.

Authors:  M Fogeda; S Navas; J Martín; M Casqueiro; E Rodríguez; C Arocena; V Carreño
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

9.  Hepatitis G virus infection in Egyptian children with chronic renal failure (single centre study).

Authors:  Ayman Mohammad Hammad; Mohammad Hosam El Deen Zaghloul
Journal:  Ann Clin Microbiol Antimicrob       Date:  2009-12-16       Impact factor: 3.944

10.  HGV/GBV-C in liver tissue and in sera from patients with chronic hepatitis C.

Authors:  P Fabris; M R Biasin; D Infantolino; L Romanó; P Benedetti; G Tositti; G P Pellizzer; A R Zanetti; C Stecca; G Marchelle; F de Lalla
Journal:  Infection       Date:  1998 Sep-Oct       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.